Magellan Health announced that it will be collaborating with Click Therapeutics to obtain Food and Drug Administration (FDA) clearance for therapeutic apps. Through this collaboration, Magellan seeks to extend its efforts in providing broad-based, digital, and data-driven programs for primary care and specialty care provider organizations.
Together, the two organizations will take advantage of each other’s resources in order to create mobile apps for consumers living with conditions such as addiction disorder, insomnia, depression, and anxiety. They will then apply for FDA clearance for these apps, citing valid scientific evidence for the safety and efficacy of such software. The two organizations previously collaborated last year, when Magellan launched its tobacco cessation program.
Magellan Health is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits, and other specialty areas of health care. Click Therapeutics engineers, validates, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification.
This was reported by Magellan Health on August 15, 2017.
Contact Information: Magellan Health, Inc., 4800 North Scottsdale Road Suite 4400, Scottsdale, Arizona 85251; (602) 572-6050; Website: www.magellanhealth.com
Contact Information: Click Therapeutics, Inc., 101 Avenue of the Americas, 8th Floor, New York, New York 10013; (646) 844-2158; Website: www.clicktherapeutics.com